![]() |
|
|
Department of Anatomy and Cell Biology, Queen's University, Kingston, Ontario, Canada (A.C.S., K.S.C., P.-G.F.); Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, California (R.M.B.); Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina (B.I.G.); and Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah (C.A.R., G.S.Y., D.L.L.)
1,1-Dichloroethylene (DCE) exposure to mice elicits lung toxicity that selectively targets bronchiolar Clara cells. The toxicity is mediated by DCE metabolites formed via cytochrome P450 metabolism. The primary metabolites formed are DCE epoxide, 2,2-dichloroacetaldehyde, and 2-chloroacetyl chloride. The major metabolite detected is 2-S-glutathionyl acetate [C], a putative conjugate of DCE epoxide with glutathione. In this investigation, studies were undertaken to test the hypothesis that CYP2E1 and CYP2F2 are involved in bioactivation of DCE to the epoxide in murine lung. We have developed a method using liquid chromatography/mass spectrometry (LC/MS) to evaluate the kinetics of the rates of production of conjugate [C] by recombinant CYP2E1 and CYP2F enzymes and lung microsomes. Concentration-dependent formation of conjugate [C] was found in incubations of DCE with recombinant CYP2E1 and CYP2F enzymes and lung microsomes from CD-1, wild-type (mixed 129/Sv and C57BL), and CYP2E1-null mice. Recombinant rat CYP2E1 exhibited greater affinity and catalytic efficiency for DCE metabolism than did recombinant human CYP2E1, mouse CYP2F2, goat CYP2F3 or rat CYP2F4. In the lung microsomal incubations, the rates of conjugate [C] production were higher in CD-1 mice than in either wild-type or CYP2E1-null mice; the level of [C] in CYP2E1-null mice was about 66% of that in wild-type mice. These results demonstrated that LC/MS analysis is a suitable method for detection and quantitation of conjugate [C], and that CYP2E1 and CYP2F2 catalyze the bioactivation of DCE to the epoxide in murine lung. The results also demonstrated that CYP2E1 is the high-affinity enzyme involved in DCE bioactivation.
This article has been cited by other articles:
![]() |
L. K. Jennings, M. M. G. Chartrand, G. Lacrampe-Couloume, B. S. Lollar, J. C. Spain, and J. M. Gossett Proteomic and Transcriptomic Analyses Reveal Genes Upregulated by cis-Dichloroethene in Polaromonas sp. Strain JS666 Appl. Envir. Microbiol., June 1, 2009; 75(11): 3733 - 3744. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Kartha and G. S. Yost Mechanism-Based Inactivation of Lung-Selective Cytochrome P450 CYP2F Enzymes Drug Metab. Dispos., January 1, 2008; 36(1): 155 - 162. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-G. Forkert, M. Kaufmann, G. Black, R. Bowers, H. Chen, K. Collins, A. Sharma, and G. Jones Oxidation of Vinyl Carbamate and Formation of 1,N6-Ethenodeoxyadenosine in Murine Lung Drug Metab. Dispos., May 1, 2007; 35(5): 713 - 720. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-G. Forkert, B. Millen, L. H. Lash, D. A. Putt, and B. I. Ghanayem Pulmonary Bronchiolar Cytotoxicity and Formation of Dichloroacetyl Lysine Protein Adducts in Mice Treated with Trichloroethylene J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 520 - 529. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-G. Forkert, R. M. Baldwin, B. Millen, L. H. Lash, D. A. Putt, M. A. Shultz, and K. S. Collins PULMONARY BIOACTIVATION OF TRICHLOROETHYLENE TO CHLORAL HYDRATE: RELATIVE CONTRIBUTIONS OF CYP2E1, CYP2F, AND CYP2B1 Drug Metab. Dispos., October 1, 2005; 33(10): 1429 - 1437. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wan, B. A. Carr, N. S. Cutler, D. L. Lanza, R. N. Hines, and G. S. Yost SP1 AND SP3 REGULATE BASAL TRANSCRIPTION OF THE HUMAN CYP2F1 GENE Drug Metab. Dispos., August 1, 2005; 33(8): 1244 - 1253. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Baldwin, M. A. Shultz, and A. R. Buckpitt Bioactivation of the Pulmonary Toxicants Naphthalene and 1-Nitronaphthalene by Rat CYP2F4 J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 857 - 865. [Abstract] [Full Text] [PDF] |
||||